Abstract
The past decade has seen the emergence of two new paradigms in inflammatory disease: first, cardiovascular complications of atherosclerosis are markedly increased in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE); and second, inflammatory mechanisms are important in the pathogenesis of atherosclerosis. These concurrent developments have lead to the concept that inflammatory mediators operative in RA and SLE might be causal in the accelerated atherosclerosis observed, a concept supported by clinical studies showing that this acceleration is not fully explained by traditional vascular risk factors. Separate lines of evidence implicate the cytokine macrophage migration inhibitory factor (MIF) in RA, SLE, and atherosclerosis. Several reports have revealed definitive in vivo evidence of the activity of MIF in a model of SLE, demonstrated a novel role for MIF in monocyte/macrophage recruitment, and showed that MIF regulates a key mediator of inflammatory cell activation. Together with evidence that MIF circulates in increased concentrations in patients with RA and SLE, this information suggests that in addition to contributing to each disease, MIF might contribute directly to the acceleration of atherosclerosis in RA and SLE.
Key Points
-
There is an increased burden of cardiovascular disease in patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), which is incompletely explained by traditional risk factors
-
Inflammation has a critical role in the molecular pathogenesis of atherosclerosis
-
Macrophage migration inhibitory factor (MIF) has been demonstrated to be involved in the pathogenesis of each of RA, SLE and atherosclerosis, and increased levels of MIF in patients with RA and SLE might contribute to accelerated atherosclerosis in those diseases
-
New reports demonstrate that MIF is involved in monocyte/macrophage recruitment, via effects on CC-chemokine ligand 2 and CXC-chemokine receptor 2 in lupus nephritis, postcapillary venules and arterial walls
-
MIF has been shown to be a key negative regulator of MAP kinase phosphatase-1
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Doria A et al. (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119: 700–706
Borchers AT et al. (2004) Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 3: 423–453
Bjornadal L et al. (2004) Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. J Rheumatol 31: 713–719
del Rincon ID et al. (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44: 2737–2745
Solomon DH et al. (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107: 1303–1307
Libby P et al. (2002) Inflammation and atherosclerosis. Circulation 105: 1135–1143
Esdaile JM et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44: 2331–2337
Goodson NJ et al. (2004) Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 43: 731–736
Hansson GK et al. (2002) Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91: 281–291
Faure E et al. (2001) Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 166: 2018–2024
Gu L et al. (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Molecular Cell 2: 275–281
Boring L et al. (1998) Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894–897
Xu XH et al. (2001) Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104: 3103–3108
Mach F et al. (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394: 200–203
Amento EP et al. (1991) Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 11: 1223–1230
Johnson JL (2007) Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 5: 265–282
Bruce IN (2005) 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 44: 1492
Manzi S et al. (1997) Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145: 408–415
Abu-Shakra M et al. (1995) Mortality studies in systemic lupus erythematosus. Results from a single centre. Causes of death. J Rheumatol 22: 1259–1264
Goodson NJ et al. (2002) Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 46: 2010–2019
Pahor A et al. (2006) Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. Rheumatol Int 27: 119–123
Hansel S et al. (2003) Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 170: 177–180
Quyyumi AA (2003) Prognostic value of endothelial function. Am J Cardiol 91: 19–24
Datta D et al. (2007) Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 192: 391–395
Esdaile JM et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44: 2331–2337
Stanic AK et al. (2006) Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci USA 103: 7018–7023
David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56: 72–77
Calandra T et al. (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179: 1895–1902
Bacher M et al. (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93: 7849–7854
Leng L et al. (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197: 1467–1476
Shi X et al. (2006) CD44 is the signaling component of the macrophage migration inhibitory factor–CD74 receptor complex. Immunity 25: 595–606
Santos LL et al. (2004) Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol 31: 1038–1043
Lue H et al. (2006) Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18: 688–703
Amin MA et al. (2003) Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 93: 321–329
Lue H et al. (2007) Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26: 5046–5059
Mitchell RA et al. (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 99: 345–350
Morand EF (2005) New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 35: 419–426
Morand EF et al. (2006) MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5: 399–410
Kim HR et al. (2007) Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol 34: 927–936
Radstake TR et al. (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52: 3020–3029
Rovensky J et al. (1975) Correlation between the results of the migration inhibitory factor production test with DNA and the severity of the disease in the systemic lupus erythematosus patients. Z Immunitatsforsch Exp Klin Immunol 150: 24–30
Mizue Y et al. (2000) Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int J Mol Med 5: 397–403
Foote A et al. (2004) Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 31: 268–273
Lan HY et al. (2000) Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57: 499–509
Brown FG et al. (2002) Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol 13 (Suppl 1): S7–S13
Sanchez E et al. (2006) Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun 7: 433–436
Burger-Kentischer A et al. (2002) Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105: 1561–1566
Lin SG et al. (2000) De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 87: 1202–1208
Atsumi T et al. (2000) Enhancement of oxidised low-density lipoprotein uptake by macrophages in response to macrophage migration inhibitory factor. Cytokine 12: 1553–1556
Schober A et al. (2004) Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109: 380–385
Pan JH et al. (2004) Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109: 3149–3153
Shimizu T et al. (2004) Macrophage migration inhibitory factor (MIF) is induced by thrombin and factor Xa in endothelial cells. J Biol Chem 279: 13729–13737
Kong YZ et al. (2005) Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc Res 65: 272–282
Kong YZ et al. (2005) Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis 178: 207–215
Hoi AY et al. (2006) Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 177: 5687–5696
Gregory JL et al. (2004) Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum 50: 3023–3034
Gregory JL et al. (2006) Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 177: 8072–8079
Bernhagen J et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13: 587–596
Liu Y et al. (2007) MAPK phosphatases—regulating the immune response. Nat Rev Immunol 7: 202–212
Abraham SM et al. (2006) Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203: 1883–1889
Salojin KV et al. (2006) Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 176: 1899–1907
Toh ML et al. (2004) Expression of MAP kinase phosphatase-1, a negative regulator of MAP kinases, in rheumatoid arthritis: upregulation by IL-1 and glucocorticoids. Arthritis Rheum 50: 3118–3128
Aeberli D et al. (2006) Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) 45: 937–943
Aeberli D et al. (2006) Macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 580: 974–981
Roger T et al. (2005) Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 35: 3405–3413
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
EF Morand is an employee and shareholder of Cortical Pty Ltd, a company engaged in the discovery of MIF antagonist compounds. The other authors declared no competing interests.
Rights and permissions
About this article
Cite this article
Ayoub, S., Hickey, M. & Morand, E. Mechanisms of Disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Rev Rheumatol 4, 98–105 (2008). https://doi.org/10.1038/ncprheum0701
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0701
This article is cited by
-
Acceleration of tumor growth due to dysfunction in M1 macrophages and enhanced angiogenesis in an animal model of autoimmune disease
Laboratory Investigation (2016)
-
Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus
Scientific Reports (2016)
-
Successes, challenges and developments in Australian rheumatology
Nature Reviews Rheumatology (2015)
-
Secondary necrotic neutrophils release interleukin-16C and macrophage migration inhibitory factor from stores in the cytosol
Cell Death Discovery (2015)
-
Baicalein Inhibits Interleukin-1β-Induced Proliferation of Human Rheumatoid Arthritis Fibroblast-like Synoviocytes
Inflammation (2014)